For health care professionals in EUROPE except those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
For broader lesion coverage and procedural confidence, the AGENTTM DCB is now available in 40mms to enhance deliverabilty for long lesions. Hear how Dr. Testa approaches DCB selection and deliverability.
The AGENTTM DCB is designed for optimal drug deliverability by combining a low-dose paclitaxel 2 µg/mm² and acetyl tributyl citrate (ATBC) Excipient coating technology (TransPaxTM). The coating is designed not only to protect the coating during delivery and support efficient drug transfer to the vessel wall, but to do so rapidly (30 seconds per IFU) .
AGENTTM was approved in Europe in 2014, and in October 2025, we added new 40mm lengths. In the US, AGENTTM became the first and only FDA-approved coronary drug-coated balloon in April 2024, approved for the treatment of coronary in-stent restenosis (ISR).
Due to the efficiency of AGENTTM Drug-Coated Balloon’s proprietary TransPaxTM Coating Technology, AGENTTM is able to use the lowest Paclitaxel (PTx) dosage compared to other PTx-coated balloons, while still resulting in the highest concentration of drug in the tissue. This allows you to deliver the optimal dose with less balloon drug load2,3.
TransPaxTM combines an acetyl tributyl citrate (ATBC) excipient with 2 µg/mm2 of crystalline, sharp-edge Paclitaxel (PTx), custom engineered around 3 key mechanisms of action:
1. Surapaneni, M., et al. "Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges." International Scholarly Research Notices (2012).
2. Tzafriri A, et al. Journal of Controlled Release. 2019; 310:94–102. Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics
3. BSC Internal Test. Results of internal bench studies are not representative of clinical performance. Clinical results may vary.
4. Speck, U,. et al., Do Pharmacokinetics Explain Persistent Restenosis Inhibition by a Single Dose of Paclitaxel?, Circ Cardiov Interv, 2012
5. Loh, JP., et al., The current status of drug-coated balloons in percutaneous coronary and peripheral interventions, EuroIntervention 2013
6. Tzafriri AR, et al., Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics. J Control Release. 2019 Sep
7. Pre-clinical pharmacokinetic studies performed using the same FDA recommended and accepted porcine coronary de nevo vessel test methodBSC conducted AGENT, SeQuent Please and Selution. Magic touch published data, TCT 2020.
8. Granada JF, et al. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart 2014
CAUTION:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com.
Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.
